Hassan Jafary, MD
Psychiatry · Beckley, WVNPI 1184771016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 1,093 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,093 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sunovion Pharmaceuticals Inc.$2K
- Corium, LLC$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- plus $8K from 35 others
What the payments were for
- Food & beverage$17,89699%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$17,991 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 141 | $204,345 |
| RexultiBrexpiprazole | 116 | $146,041 |
| TrintellixVortioxetine Hydrobromide | 163 | $93,287 |
| NuedextaDextromethorphan Hbr/Quinidine | 56 | $81,171 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $47,313 |
| AuvelityDextromethorphan Hbr/Bupropion | 31 | $39,688 |
| FanaptIloperidone | 12 | $30,113 |
| VivitrolNaltrexone Microspheres | 12 | $18,512 |
| Lurasidone Hcl | 116 | $15,973 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 187 | $14,443 |
| VyvanseLisdexamfetamine Dimesylate | 35 | $13,938 |
| Aripiprazole | 655 | $11,878 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $8,091 |
| BelsomraSuvorexant | 14 | $6,885 |
| Ziprasidone Hcl | 130 | $6,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Namzaric | $2,866 | $212,436153 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,387 | $146,041116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $888 | $107,225198 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $470 | $81,17156 claims |
| Alkermes, Inc.Lybalvi, Vivitrol | $1,167 | $65,82543 claims |
| Axsome Therapeutics, Inc.Auvelity | $397 | $39,68831 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $664 | $30,11312 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $35 | $14,443187 claims |
| MerckBelsomra | $48 | $6,88514 claims |
| Indivior Inc.Suboxone | $440 | $3,91030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.
Other psychiatry in Beckley
- Ahmed FaheemBeckley$82K
- Jawad ZafarBeckley$15K
- Omar HasanBeckley$5K
- Safiullah SyedBeckley$784
- Melissa MoodyCharleston$1.2M
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
- Daniel ThistlethwaiteSouth Charleston$468K
- Walter ByrdMorgantown$299K
- Fahd MousaCharleston$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.